SEC Form 4
Edwards Lifesciences Corp (EW) insider trading
In the 12 months to Oct 24, 2026, 9 EW insiders reported open-market sales of $27.7M across 41 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $27.7M
- 41 filings · 9 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 23 of 41
- $14.5M of $27.7M sold (52%)
Who traded EW, and when
- Sale
- Sale, pre-arranged (10b5-1)
EW daily close from Oct 24, 2025 to Oct 23, 2026, between $75.87 and $95.18, last $89.07. 41 sale and 0 purchase filings by 9 insiders, marked at their filing dates. Donald E. Bobo Jr., CVP,Strategy/Corp Development: sold $11.2M across 8 filings, first filed Dec 10, 2025, last May 27, 2026. Bernard J. Zovighian, CEO: sold $7.0M across 5 filings, first filed Dec 10, 2025, last Jul 27, 2026. Scott B. Ullem, CVP, Chief Financial Officer: sold $3.9M across 4 filings, first filed Nov 10, 2025, last Apr 9, 2026. Daveen Chopra, CVP, TMTT & Surgical → CVP, TMTT, Surgical & IHFM: sold $3.2M across 3 filings, first filed Dec 11, 2025, last Aug 26, 2026. Wayne Markowitz, CVP, JAPAC: sold $1.0M across 5 filings, first filed Dec 8, 2025, last Aug 26, 2026. Daniel J. Lippis, CVP, JAPAC → CVP, TAVR: sold $924.6K across 12 filings, first filed Nov 10, 2025, last Oct 8, 2026. 3 others: sold $554.4K across 4 filings, first filed Dec 12, 2025, last Aug 31, 2026.
Largest mark · tap a row for others
Donald E. Bobo Jr. · CVP,Strategy/Corp Development
Filing 1 of 2 within a week · $2,986,506 total
Sale $2,012,076
24,000 shares at $83.84 avg
Filed Feb 26, 2026 · traded Feb 25
Close on filing date $85.90
Donald E. Bobo Jr. · CVP,Strategy/Corp Development
CVP,Strategy/Corp Development
$11.2M soldBernard J. Zovighian · CEO
CEO
$7.0M soldScott B. Ullem · CVP, Chief Financial Officer
CVP, Chief Financial Officer
$3.9M soldDaveen Chopra · CVP, TMTT & Surgical → CVP, TMTT, Surgical & IHFM
CVP, TMTT & Surgical → CVP, TMTT, Surgical & IHFM
$3.2M soldWayne Markowitz · CVP, JAPAC
CVP, JAPAC
$1.0M soldDaniel J. Lippis · CVP, JAPAC → CVP, TAVR
CVP, JAPAC → CVP, TAVR
$924.6K sold3 others
Combined, one mark per week
$554.4K soldHas Edwards Lifesciences Corp's CEO sold stock?
Yes. Bernard J. Zovighian (CEO) sold 87,575 shares ($7.0M) between Dec 2025 and Jul 2026, $5.0M of it under a pre-arranged 10b5-1 plan.
Open-market trades
41 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Donald E. Bobo Jr. | CVP,Strategy/Corp Development | $11.2M | — | 8 | 42% of sales | |
| Bernard J. Zovighian | CEO | $7.0M | — | 5 | 72% of sales | |
| Scott B. Ullem | CVP, Chief Financial Officer | $3.9M | — | 4 | 100% of sales | |
| Daveen Chopra | CVP, TMTT & Surgical → CVP, TMTT, Surgical & IHFM | $3.2M | — | 3 | — | |
| Wayne Markowitz | CVP, JAPAC | $1.0M | — | 5 | — | |
| Daniel J. Lippis | CVP, JAPAC → CVP, TAVR | $924.6K | — | 12 | 100% of sales | |
| Annette Bruls | CVP, EMEACLA | $237.9K | — | 1 | — | |
| Heisz Leslie Stone | Director | $218.1K | — | 1 | — | |
| Andrew M. Dahl | SVP, Corporate Controller | $98.4K | — | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 619 | $85.65 | $53.0K | 40,034 | |
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 619 | $87.51 | $54.2K | 40,034 | |
traded | Andrew M. Dahl SVP, Corporate Controller | Sale | 544 | $91.06 | $49.5K | 14,868 | |
traded | Annette Bruls CVP, EMEACLA | Sale | 2,644 | $89.98 | $237.9K | 17,984 | |
traded | Wayne Markowitz CVP, JAPAC | Sale | 1,240 | $91.47 | $113.4K | 20,294 | |
traded | Daveen Chopra CVP, TMTT, Surgical & IHFM | Sale | 31,800 | $91.02 | $2.9M | 44,324 | |
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 619 | $92.03 | $57.0K | 40,034 | |
traded | Wayne Markowitz CVP, JAPAC | Sale | 146 | $86.03 | $12.6K | 21,534 | |
traded | Wayne Markowitz CVP, JAPAC | Sale | 9,628 | $85.06 | $819.0K | 21,680 | |
traded | Bernard J. Zovighian CEO | Sale | 2,921 | $83.93 | $245.1K | 8,916 | |
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 619 | $91.70 | $56.8K | 40,034 | |
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 619 | $91.40 | $56.6K | 40,411 | |
traded | Bernard J. Zovighian CEO | SalePre-arranged (10b5-1) | 523 | $87.92 | $46.0K | 11,517 | |
traded | Andrew M. Dahl SVP, Corporate Controller | Sale | 568 | $86.08 | $48.9K | 15,334 | |
traded | Donald E. Bobo Jr. CVP,Strategy/Corp Development | Sale | 23,145 | $86.42 | $2.0M | 98,611 | |
traded | Daveen Chopra CVP, TMTT & Surgical | Sale | 1,500 | $84.60 | $126.9K | 44,324 | |
traded | Donald E. Bobo Jr. CVP,Strategy/Corp Development | Sale | 17,968 | $81.96 | $1.5M | Multiple accounts | |
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 620 | $81.14 | $50.3K | 40,411 | |
traded | Bernard J. Zovighian CEO | SalePre-arranged (10b5-1) | 36,351 | $77.93 | $2.8M | 12,040 | |
traded | Wayne Markowitz CVP, JAPAC | Sale | 593 | $79.73 | $47.3K | 21,680 | |
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 2,038 | $83.49 | $170.2K | 33,682 | |
traded | Scott B. Ullem CVP, Chief Financial Officer | SalePre-arranged (10b5-1) | 13,000 | $80.04 | $1.0M | 39,699 | |
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 1,019 | $80.98 | $82.5K | 33,934 | |
traded | Donald E. Bobo Jr. CVP,Strategy/Corp Development | SalePre-arranged (10b5-1) | 22,680 | $80.16 | $1.8M | 21,266 | |
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 1,019 | $85.38 | $87.0K | 33,934 | |
traded | Scott B. Ullem CVP, Chief Financial Officer | SalePre-arranged (10b5-1) | 13,000 | $84.92 | $1.1M | 39,699 | |
traded | Donald E. Bobo Jr. CVP,Strategy/Corp Development | SalePre-arranged (10b5-1) | 11,340 | $85.93 | $974.4K | 21,266 | |
traded | Donald E. Bobo Jr. CVP,Strategy/Corp Development | Sale | 24,000 | $83.84 | $2.0M | 21,266 | |
traded | Bernard J. Zovighian CEO | Sale | 22,430 | $76.67 | $1.7M | 83,896 | |
traded | Daniel J. Lippis CVP, TAVR | SalePre-arranged (10b5-1) | 1,019 | $85.70 | $87.3K | 22,002 | |
traded | Donald E. Bobo Jr. CVP,Strategy/Corp Development | SalePre-arranged (10b5-1) | 11,340 | $85.66 | $971.4K | 40,578 | |
traded | Heisz Leslie Stone Director | Sale | 2,615 | $83.41 | $218.1K | 30,948 | |
traded | Daniel J. Lippis CVP, JAPAC | SalePre-arranged (10b5-1) | 1,019 | $84.03 | $85.6K | 22,002 | |
traded | Donald E. Bobo Jr. CVP,Strategy/Corp Development | Sale | 11,386 | $83.76 | $953.7K | 44,870 | |
traded | Daveen Chopra CVP, TMTT & Surgical | Sale | 2,000 | $84.38 | $168.8K | 32,201 | |
traded | Bernard J. Zovighian CEO | SalePre-arranged (10b5-1) | 25,350 | $84.95 | $2.2M | Multiple accounts | |
traded | Donald E. Bobo Jr. CVP,Strategy/Corp Development | SalePre-arranged (10b5-1) | 11,340 | $83.83 | $950.6K | 50,356 | |
traded | Scott B. Ullem CVP, Chief Financial Officer | SalePre-arranged (10b5-1) | 7,700 | $84.47 | $650.4K | 39,898 | |
traded | Wayne Markowitz CVP, JAPAC | Sale | 583 | $86.01 | $50.1K | 17,563 | |
traded | Daniel J. Lippis CVP, JAPAC | SalePre-arranged (10b5-1) | 1,020 | $82.55 | $84.2K | 22,002 | |
traded | Scott B. Ullem CVP, Chief Financial Officer | SalePre-arranged (10b5-1) | 13,000 | $83.08 | $1.1M | 49,924 |
GET /stocks/filings/vX/form-4?tickers=EW&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"EW"
],
"issuer_cik": "0001099800",
"owner_cik": "0002004380",
"accession_number": "0001225208-26-008338",
"form_type": "4",
"filing_date": "2026-10-08",
"period_of_report": "2026-10-08",
"issuer_name": "Edwards Lifesciences Corp",
"issuer_trading_symbol": "EW",
"owner_name": "Lippis Daniel J.",
"is_officer": true,
"officer_title": "CVP, TAVR",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-08",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 619,
"transaction_price_per_share": 85.65,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 40033.9103,
"transaction_value": 53017.350000000006,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026."
}
],
"remarks": "This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person."
},
{
"tickers": [
"EW"
],
"issuer_cik": "0001099800",
"owner_cik": "0002004380",
"accession_number": "0001225208-26-007774",
"form_type": "4",
"filing_date": "2026-09-11",
"period_of_report": "2026-09-11",
"issuer_name": "Edwards Lifesciences Corp",
"issuer_trading_symbol": "EW",
"owner_name": "Lippis Daniel J.",
"is_officer": true,
"officer_title": "CVP, TAVR",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-11",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 619,
"transaction_price_per_share": 87.51,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 40033.9103,
"transaction_value": 54168.69,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026."
}
],
"remarks": "This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person."
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 103 records
- Option exercises30 records
- Tax withholding36 records
- Grants and awards22 records
- Gifts15 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for EW every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.